meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - triple negative
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
es-BC - TNBC - NA - all population
5
es-BC - TNBC - NA - PDL1 positive
1
es-BC - Triple negatif (TNBC) - 1st line (L1)
mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
mBC - Triple negative (TNBC) - 1st Line (L1)
1
mBC - TNBC - L1 - all population
7
mBC - TNBC - L1 - PDL1 positive
4
mBC-Triple negative (TNBC) - 2nd Line (L2)
3
mBC - TNBC - L2 - all population
2
mBC - TNBC - L2 - PDL1 positive
2
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
poly ADP-ribose polymerase (PARP) inhibitor
olaparib
versus all
vs chemotherapy
vs Standard of Care (SoC)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
olaparib
title
Standard of Care (SoC)
title
OlympiAD, 2017 NCT02000622 mBC - TNBC - L2 - all population 205/97
Pathology:
mBC - TNBC - L2 - all population;
mBC - TNBC - L2 - all population
OlympiAD, 2017
olaparib
1
T1
Standard of Care (SoC)
0
T0